JP2016522159A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522159A5
JP2016522159A5 JP2016503339A JP2016503339A JP2016522159A5 JP 2016522159 A5 JP2016522159 A5 JP 2016522159A5 JP 2016503339 A JP2016503339 A JP 2016503339A JP 2016503339 A JP2016503339 A JP 2016503339A JP 2016522159 A5 JP2016522159 A5 JP 2016522159A5
Authority
JP
Japan
Prior art keywords
item
peptide
composition according
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522159A (ja
JP6603207B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/030147 external-priority patent/WO2014145389A1/en
Publication of JP2016522159A publication Critical patent/JP2016522159A/ja
Publication of JP2016522159A5 publication Critical patent/JP2016522159A5/ja
Priority to JP2018134098A priority Critical patent/JP6975690B2/ja
Application granted granted Critical
Publication of JP6603207B2 publication Critical patent/JP6603207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503339A 2013-03-15 2014-03-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害 Active JP6603207B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018134098A JP6975690B2 (ja) 2013-03-15 2018-07-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800117P 2013-03-15 2013-03-15
US61/800,117 2013-03-15
PCT/US2014/030147 WO2014145389A1 (en) 2013-03-15 2014-03-17 Inhibition of pulmonary fibrosis with nutlin-3a and peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018134098A Division JP6975690B2 (ja) 2013-03-15 2018-07-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害

Publications (3)

Publication Number Publication Date
JP2016522159A JP2016522159A (ja) 2016-07-28
JP2016522159A5 true JP2016522159A5 (https=) 2017-04-20
JP6603207B2 JP6603207B2 (ja) 2019-11-06

Family

ID=51537978

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016503339A Active JP6603207B2 (ja) 2013-03-15 2014-03-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP2018134098A Active JP6975690B2 (ja) 2013-03-15 2018-07-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP2021128989A Active JP7378833B2 (ja) 2013-03-15 2021-08-05 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP2023183297A Pending JP2023178440A (ja) 2013-03-15 2023-10-25 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018134098A Active JP6975690B2 (ja) 2013-03-15 2018-07-17 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP2021128989A Active JP7378833B2 (ja) 2013-03-15 2021-08-05 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害
JP2023183297A Pending JP2023178440A (ja) 2013-03-15 2023-10-25 ヌトリン３ａおよびペプチドを用いた肺線維症の阻害

Country Status (11)

Country Link
US (8) US9630990B2 (https=)
EP (3) EP4438044A3 (https=)
JP (4) JP6603207B2 (https=)
KR (3) KR102588702B1 (https=)
CN (3) CN110201144B (https=)
AU (3) AU2014233055B2 (https=)
CA (1) CA2904870C (https=)
DK (2) DK2970383T3 (https=)
ES (2) ES2875853T3 (https=)
PT (2) PT3929207T (https=)
WO (1) WO2014145389A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
CN110201144B (zh) * 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
GB201421092D0 (en) * 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
WO2016138413A1 (en) * 2015-02-27 2016-09-01 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2018190680A1 (ko) * 2017-04-13 2018-10-18 충남대학교산학협력단 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법
KR102082285B1 (ko) * 2017-04-13 2020-02-28 충남대학교산학협력단 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법
CN107987128B (zh) 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
US12281180B2 (en) 2018-07-13 2025-04-22 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
KR20210057127A (ko) 2018-09-10 2021-05-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis
CN109010798A (zh) * 2018-09-17 2018-12-18 中山大学中山眼科中心 一种多肽的新用途
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
EP4086275A4 (en) * 2019-12-31 2024-04-17 Xiamen University Multimerization delivery system for intracellular delivery of molecule
US20250076312A1 (en) 2021-02-25 2025-03-06 Lung Therapeutics, Llc Biomarkers for the treatment of interstitial lung disease
WO2022217037A1 (en) * 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN119258210A (zh) * 2023-07-06 2025-01-07 厦门大学 新型疫苗递送体系
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4021387A (en) 1975-11-19 1977-05-03 President And Fellows Of Harvard College Eosinophilotactic tetrapeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
ZA846192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
DK53291D0 (da) * 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
JP3401005B2 (ja) * 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US20030113271A1 (en) 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
BR0215157A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
CN101022830A (zh) * 2004-05-25 2007-08-22 阿特努奥恩公司 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
CN102131827A (zh) 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
WO2009079692A1 (en) * 2007-12-21 2009-07-02 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
WO2009111625A2 (en) 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
JP5859307B2 (ja) 2008-09-10 2016-02-10 ジェネンテック， インコーポレイテッド 眼の血管新生を阻害する方法
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
PT3501499T (pt) 2010-02-11 2022-11-22 Ablynx Nv Métodos e composições para a preparação de aerossóis
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
BR112015022831A2 (pt) 2013-03-13 2017-08-22 Forest Laboratories Holdings Ltd Composições farmacêuticas micronizadas
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
MX2016005720A (es) 2013-11-04 2016-11-25 Univ Texas Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.
WO2015080980A2 (en) 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
WO2015080943A1 (en) 2013-11-26 2015-06-04 Yale University Novel cell-penetrating compositions and methods using same
KR20210057127A (ko) 2018-09-10 2021-05-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법
AU2019339260B2 (en) 2018-09-10 2025-06-26 Rein Therapeutics, Inc. Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis

Similar Documents

Publication Publication Date Title
JP2016522159A5 (https=)
US12303550B2 (en) Neuroprotective peptides
AU765584B2 (en) Protein formulations
US20150307575A1 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US20100105753A1 (en) Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof
CA2845357A1 (en) Method of treating or ameliorating type 1 diabetes using fgf21
KR102483333B1 (ko) 경구 점막염 치료에 사용하기 위한 신규한 펩티드 및 유사체
CA2223832A1 (en) Method for the treatment of corticosteroid induced osteopenia
JP2018515101A5 (https=)
CN103619347A (zh) Fgf-18冷冻干燥制剂
DK2720707T3 (en) Anti-inflammatory pharmaceutical products
JP2013525406A (ja) 安定ｍｉａ／ｃｄ−ｒａｐ製剤
KR101283736B1 (ko) 케라티노사이트 성장 인자의 치료학적 제형
JP2016519670A5 (https=)
KR20170005118A (ko) 펩티드 담체 상의 다중 올리고뉴클레오티드 모이어티
CN116669752B (zh) Glp-1/glp-2双重激动剂的药物组合物
JP2015519359A5 (https=)
EP1272510B1 (en) Pharmacologically active antiviral peptides and methods of their use
US20130165376A1 (en) Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation
WO2009038729A2 (en) Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
AU2016232361B2 (en) Cyclic galanin-analogs and uses thereof
CN101808655A (zh) 衍生自纤溶酶原激活物抑制剂-1的肽和其应用
US10213493B2 (en) Protein to promote blood vessel growth and uses thereof
CN114080394A (zh) 新型θ-防御素类似物
JP2002539829A5 (https=)